Cardiome -- CRME Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cardiome -- CRME

CRME 2.330

-2.1%

May 16 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI	9/27/2006 4:19:50 PM
	Read Replies (1) of 285

What an ugly name! VANCOUVER, Sept. 27 /CNW/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that RSD1235 has been assigned the name vernakalant hydrochloride by the United States Adopted Names (USAN) Council. All future references to RSD1235 (iv) will now be vernakalant (iv), and references to RSD1235 (oral) will be vernakalant (oral). The commercial brand name for vernakalant (iv) will be finalized in the coming months. Cardiome was also recently granted U.S. Patent No. 7,057,053 titled "Ion Channel Modulating Compounds and Uses Thereof", related to the composition of vernakalant and expiring October 16, 2020 absent any extensions. Counterpart applications are pending worldwide.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next